NEW YORK, July 23 - Compugen licensed its Gencarta database of annotated genomic, transcription, and proteomic data to the Albert Einstein College of Medicine of Yeshiva University and the Weizmann Institute of Science, the company announced Monday.
Financial details of the agreements were not disclosed.
"Gencarta complements our established functional genomics program and will greatly accelerate disease-oriented gene discovery by investigators at our institution," Erwin Bottinger, director of the Albert Einstein Biotechnology Center at the Albert Einstein College of Medicine of Yeshiva University, said in a statement.
Compugen, headquartered in Tel Aviv, Israel, released Gencarta in March. The database uses Compugen's Leads algorithm to provide annotation of the transcription factors that bridge genes and proteins. Leads takes into account alternative splicing, in which exons, or coding regions, on one gene can combine in different ways to form different proteins.
The agreements with Albert Einstein College of Medicine and the Weizmann Institute of Science brings Compugen's Gencarta customers to four. The other licensees are the Japanese pharmaceutical company Kyowa-Hakko Kogyo and Avalon Pharmaceuticals of Gaithersburg, Md.